Kalbe Farma Tbk

KLBF

+3.65%

Overview

KLBF Overview

PT Kalbe Farma Tbk is an Indonesia-based company, which is engaged in the development, manufacturing and trading of pharmaceutical products including human medicines and consumer health products. Its business divisions include Prescription Pharmaceutical, Consumer Health Division, Nutritionals, and Distribution and Logistic divisions. The Prescription Pharmaceuticals division provides a range of products for all groups, from unbranded generic drugs for the mass-market segment, to branded generics and licensed drugs. The Consumer Health division's product portfolio spans from over the counter (OTC) drugs and energy drinks to a selection of ready-to-drink healthy beverage products. The Nutritional division manages a range of nutritional products, comprising of powdered milk products for all age segments. It also offers a selection of non-milk nutritional products. The Distribution and Logistics Division operates the distribution coverage for pharmaceuticals products in Indonesia.

5101520ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: KLBF

Main
Market Cap.
IDR 72.16Trillion
#26 in Indonesia

~$4.51B USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

KLBF Valuation Metrics

1,560

IDR
+3.7%

Closing Price on 2024-05-22

Price to Equity

26.08

P/E

At 26.08x P/E TTM, KLBF.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 10.9x).

Price to Book

3.37

P/B

At 3.37x P/B TTM, KLBF.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 1.7x).

Price to Sales

2.37

P/S

At 2.37x P/S TTM, KLBF.JK is trading at a premium to its peers in the Pharmaceuticals & Health Care Research sector (avg 0.8x).

Valuing Kalbe Farma Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing Kalbe Farma Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
24.82x
Price/Forward Earnings
20.53x
Enterprise Value/Revenue
2.28x
Enterprise Value/EBITDA
17.25x
PEG Ratio
-1.20x

Analyst Ratings

40
60
80
0
100

52.5

Recommended

Neutral

Not Recommended

Last closing: IDR1,5602024-05-22
IDR 1,121.94

Slightly Lower Intrinsic Value: Analyst's intrinsic value is of KLBF is IDR1,122, which is 27% lower than KLBF's last closing price of IDR1,560 (as of 2024-05-22).

Valuation Recap of KLBF stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 26.08x is above the ID market average of 8.70x and is trading at a premium to peers in the Pharmaceuticals & Health Care Research sector (10.87x). In fact, less than 25% of its peers trade at a higher P/E ratio than KLBF.

High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 3.37x is above the peers average of 1.74x in the Pharmaceuticals & Health Care Research sector. KLBF trades at a higher P/B ratio than >75% of its peers in the Pharmaceuticals & Health Care Research sector.

Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 2.37x is above the peers average of 0.84x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of KLBF's valuation relative to its current sales and future earnings growth. KLBF trades at a Forward P/E ratio of 20.53x, which is considered richly valued by analysts.

Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. KLBF's P/CF ratio of 24.82x is considered a relatively high ratio by analysts.

Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. KLBF's EV/R ratio of 2.28x is considered fairly underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.41x.

Medium
Slightly Lower Intrinsic Value: Analyst's intrinsic value is of KLBF is IDR 1,121.94, which is 27% lower than KLBF's last closing price of IDR 1,560.00.

Peers

KLBF Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk72.16T27.06T 30.45T 2.77T 26.083.37
MIKAPT Mitra Keluarga Karyasehat Tbk.42.97T7.34T 4.26T 0.92T 46.917.38
SILOPT Siloam International Hospitals Tbk.32.72T10.98T 11.19T 1.21T 27.014.13
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk21.45T3.89T 3.57T 0.95T 22.566.34
SRAJSejahteraraya Anugrahjaya Tbk20.58T5.61T 2.50T -0.04T -534.7211.09
HEALPT Medikaloka Hermina Tbk.19.88T8.80T 5.78T 0.44T 45.455.14
PRAYPT Famon Awal Bros Sedaya Tbk9.35T4.70T 1.84T 0.22T 43.113.34
TSPCTempo Scan Pacific Tbk9.16T11.32T 13.12T 1.18T 7.781.19
SOHOPT Soho Global Health Tbk6.32T4.75T 8.20T 0.37T 17.022.63
OMEDPT Jayamas Medica Industri Tbk5.47T2.58T 1.74T 0.26T 21.072.46
Competitiveness Recap of KLBF stock
WeightNotesScore
High
At a market cap of IDR 72,158.74 billion, KLBF.JK ranks 1 in Market Cap out of 10 companies in the Healthcare sector.

High
At a PE of 26.08, KLBF.JK ranks 5 out of 10 companies in the Healthcare sector for P/E value. The average PE is -27.77 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Mitra Keluarga Karyasehat Tbk. (46.91) in the Healthcare sector.

Medium
At a PE of 26.08, KLBF.JK is trading at a higher PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 10.87). false

Medium
At a revenue of IDR 30.45 trillion, KLBF.JK ranks 1 in Revenue out of 10 companies in the Healthcare sector.

Medium
At a profit of IDR 2.77 trillion, KLBF.JK ranks 1 in Profit out of 10 companies in the Healthcare sector.

Future

Future Growth of KLBF

Growth Forecasts

KLBF 2024 Revenue Growth
+6.8%
KLBF 2025 Revenue Growth
+14.7%
KLBF 2024 EPS Growth
+12.8%
KLBF 2025 EPS Growth
+24.9%
Sector Revenue Growth
+14.7%
Pharmaceuticals & Health Care Research
Indonesia Market Growth
+13.8%
IDX overall growth
Pharmaceuticals & Health Care Research Sector Revenue Growth '24
-5.8%
Pharmaceuticals & Health Care Research Sector Revenue Growth '25
+15.8%
Healthcare Sector Revenue Growth '24
-5.8%
Healthcare Sector Revenue Growth '25
+20.0%

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are growing at a projected rate of 14.72% against the IDX average of +13.8%.

Pharmaceuticals & Health Care Research sector overview

KLBF Earnings & Revenue Forecast

All values in IDR billion

Future growth prospect of KLBF
WeightNotesScore
High
KLBF's projected growth rate of 14.72% is above the ID market average of 13.80%.

High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 15.79% in 2025. This number is higher than the previous year 2024's growth rate of -5.79%. This bodes well for KLBF's revenue growth prospects in the next 2 years.

Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 24.87% in 2025. This number is higher than the previous year 2024's EPS growth of 0.00%. This bodes well for KLBF's earnings growth prospects in the next 2 years.

Medium
KLBF and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2025. Specifically, earnings are projected to increase by 22.78% in 2025 while revenue growth is projected to increase by 20.04%. These macroeconomic trends will likely be a tailwind for KLBF's earnings growth prospects in the next 2 years.

Loading...
Loading...

Management

Executive Management

President Director

Vidjongtius15.2 years
Bernadus Karmin Winata
Director
Sie Djohan
Director
Mulialie
Director
Jos Iwan Atmadjaja
Director
Kartika Setiabudy
Director
NamePositionShares%
B. R. Irawati SetiadyCommissioner21,588,0000.05
MulialieDirector250,045< 0.01
Ronny HadianaCommissioner91,071,0070.19
Expressed in millions IDR, unless otherwise stated

Ownership

KLBF Ownership

Others
27.38%
Insiders
58.23%
Institutions
14.39%
NameNumber of SharesOwnership (%)Value
Public (Scripless)18,867,155,17840.2529,432.76B
Ladang Ira Panen, Pt4,903,185,74010.467,648.97B
Gira Sole Prima, Pt4,824,509,48510.297,526.23B
Santa Seha Sanadi, Pt 4,718,121,94010.077,360.27B
Diptanala Bahana, Pt4,454,807,0409.56,949.50B
Lucasta Murni Cemerlang, Pt4,439,895,4409.476,926.24B
Bina Arta Charisma, Pt3,842,039,0408.25,993.58B
Treasury Stock619,480,7001.32966.39B
Public (Scrip)93,018,4950.2145.11B
Ronny Hadiana91,071,0070.19142.07B
B. R. Irawati Setiady21,588,0000.0533.68B

Largest Institutional Buy

Capital Research and Management Company
Bought 31-12-2023
+73,750,000 shares
Capital Guardian Trust Company
Bought 31-12-2023
+24,750,000 shares
Capital International Inc
Bought 31-12-2023
+24,750,000 shares

Largest Institutional Sell

No data is available for KLBF at the moment.

Institutional Transactions

Tracking institutional transactions buying / selling of KLBF stock